Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

1(20.0%)

Phase 4

1(20.0%)

Phase 1

1(20.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

5Total

Phase 3(1)

Phase 4(1)

Phase 1(1)

Phase 2(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05291390Phase 2Unknown

Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)

Role: collaborator

NCT01540903Phase 1Completed

Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults

Role: collaborator

NCT02199951Unknown

Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania

Role: collaborator

NCT00164255Phase 4Completed

Efficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy

Role: collaborator

NCT00817713Not ApplicableTerminated

Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?

Role: collaborator

NCT00152204Phase 3Unknown

The Community Effectiveness of IPTi in Southern Tanzania

Role: collaborator

NCT00153491Completed

Adherence to Lumefantrine-Artemether

Role: collaborator

All 7 trials loaded